Nader Donzel

Abionic, an in vitro diagnostics (IVD) company, was founded in 2010 as a spin-off from the Swiss Federal Institute of Technology of Lausanne (EPFL). Abionic is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

Three core activities Investment Services: We introduce investment opportunities in venture capital and private equity thanks to our highly skilled team members with a wealth of experience in their respective fields of medtech and biotech, new technologies, the hotel industry, real estate, art. We also assist start-up and scale-up companies in their development, defining business models, expansion strategies, regulatory compliance, etc. Private client services: We offer 360° solutions for international families, including "Legal services", "Trust services" and general "Family office services" Commercial services: We act as distributors of commercial goods with an emphasize on Swiss-Chinese import/export thanks to our Chinese team based in Shanghai and in Switzerland.

Abionic, an in vitro diagnostics (IVD) company, was founded in 2010 as a spin-off from the Swiss Federal Institute of Technology of Lausanne (EPFL). Abionic is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

Three core activities Investment Services: We introduce investment opportunities in venture capital and private equity thanks to our highly skilled team members with a wealth of experience in their respective fields of medtech and biotech, new technologies, the hotel industry, real estate, art. We also assist start-up and scale-up companies in their development, defining business models, expansion strategies, regulatory compliance, etc. Private client services: We offer 360° solutions for international families, including "Legal services", "Trust services" and general "Family office services" Commercial services: We act as distributors of commercial goods with an emphasize on Swiss-Chinese import/export thanks to our Chinese team based in Shanghai and in Switzerland.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs with a focus in oncology, and expanding its test menu in infectious diseases with partners. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis’ vision is to enable personalized medicine for patients around the world through universal access to molecular testing. Our mission is to make molecular testing actionable, convenient, fast and suitable for any lab. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com